DE60018050T2 - VERWENDUNG VON STABILISIERTEn OLIGONUCLEOTIDEn ZUR HERSTELLUNG VON ANTITUMORALen ARZNEIMITTELn - Google Patents

VERWENDUNG VON STABILISIERTEn OLIGONUCLEOTIDEn ZUR HERSTELLUNG VON ANTITUMORALen ARZNEIMITTELn Download PDF

Info

Publication number
DE60018050T2
DE60018050T2 DE60018050T DE60018050T DE60018050T2 DE 60018050 T2 DE60018050 T2 DE 60018050T2 DE 60018050 T DE60018050 T DE 60018050T DE 60018050 T DE60018050 T DE 60018050T DE 60018050 T2 DE60018050 T2 DE 60018050T2
Authority
DE
Germany
Prior art keywords
oligonucleotides
stabilized
stabilized oligonucleotides
tumor
route
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60018050T
Other languages
German (de)
English (en)
Other versions
DE60018050D1 (de
Inventor
Antoine Carpentier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé et de la Recherche Médicale
Original Assignee
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé et de la Recherche Médicale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique - Hôpitaux de Paris, Institut National de la Santé et de la Recherche Médicale filed Critical Assistance Publique - Hôpitaux de Paris
Publication of DE60018050D1 publication Critical patent/DE60018050D1/de
Application granted granted Critical
Publication of DE60018050T2 publication Critical patent/DE60018050T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
DE60018050T 1999-03-19 2000-03-17 VERWENDUNG VON STABILISIERTEn OLIGONUCLEOTIDEn ZUR HERSTELLUNG VON ANTITUMORALen ARZNEIMITTELn Expired - Lifetime DE60018050T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9903433 1999-03-19
FR9903433A FR2790955B1 (fr) 1999-03-19 1999-03-19 Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
PCT/FR2000/000676 WO2000056342A2 (fr) 1999-03-19 2000-03-17 Utilisation d'oligonucleotides stabilises pour la preparation d'un medicament a action antitumorale

Publications (2)

Publication Number Publication Date
DE60018050D1 DE60018050D1 (de) 2005-03-17
DE60018050T2 true DE60018050T2 (de) 2006-02-23

Family

ID=9543401

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60018050T Expired - Lifetime DE60018050T2 (de) 1999-03-19 2000-03-17 VERWENDUNG VON STABILISIERTEn OLIGONUCLEOTIDEn ZUR HERSTELLUNG VON ANTITUMORALen ARZNEIMITTELn

Country Status (12)

Country Link
US (2) US7700569B1 (enExample)
EP (1) EP1162982B9 (enExample)
JP (1) JP2002539265A (enExample)
AT (1) ATE288759T1 (enExample)
AU (1) AU3300600A (enExample)
CA (1) CA2371990A1 (enExample)
DE (1) DE60018050T2 (enExample)
DK (1) DK1162982T3 (enExample)
ES (1) ES2235839T3 (enExample)
FR (1) FR2790955B1 (enExample)
PT (1) PT1162982E (enExample)
WO (1) WO2000056342A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2711670B1 (fr) * 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DK1077722T3 (da) 1998-05-22 2006-11-27 Ottawa Health Research Inst Fremgangsmåder og produkter til induktion af mukosaimmunitet
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
DE60044236D1 (de) 1999-02-17 2010-06-02 Csl Ltd Immunogene komplexe und methoden in bezug auf diese
FR2790955B1 (fr) * 1999-03-19 2003-01-17 Assist Publ Hopitaux De Paris Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
EA007232B1 (ru) 2001-08-17 2006-08-25 Коли Фармасьютикал Гмбх Иммуностимулирующие олигонуклеотиды, содержащие комбинацию мотивов и обладающие повышенной активностью
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
NZ540098A (en) 2002-10-29 2008-09-26 Coley Pharmaceutical Group Ltd Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
US10100316B2 (en) * 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
US7956043B2 (en) 2002-12-11 2011-06-07 Coley Pharmaceutical Group, Inc. 5′ CpG nucleic acids and methods of use
CA2542099A1 (en) * 2003-10-11 2005-04-21 Inex Pharmaceuticals Corporation Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
EP1649859A1 (fr) * 2004-10-22 2006-04-26 Institut Gustave Roussy Produits pharmaceutiques contenant au moins un principe actif anticancereux peu diffusible et un principe actif immunostimulant sous forme d'oligodésoxynucléotide
WO2006010838A2 (fr) * 2004-06-25 2006-02-02 Institut Gustave Roussy Produits contenant au moins un principe actif anticancereux peu diffusible et un principe actif immunostimulant
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
KR20070110901A (ko) 2005-03-04 2007-11-20 다이나박스 테크놀로지 코퍼레이션 항원에 콘쥬게이트되고 버퍼 조건 및 추가의 부형제들에의해 안정화된 면역자극성 서열(ｉｓｓ)을 갖는올리고뉴클레오티드를 포함하는 백신
JP5646320B2 (ja) 2007-05-11 2014-12-24 アダイニクス， インコーポレイテッド 遺伝子発現と疼痛
FR2975600B1 (fr) 2011-05-24 2013-07-05 Assist Publ Hopitaux De Paris Agents pour le traitement de tumeurs
US20130210896A1 (en) * 2011-11-09 2013-08-15 City Of Hope Immunotheraphy of Brain Tumors Using a Nanoparticle CpG Delivery System
RU2668136C2 (ru) 2012-05-10 2018-09-26 Эйдинкс, Инк. Композиции для доставки активных ингредиентов
CN106661578B (zh) 2014-08-15 2020-08-04 埃迪恩克斯股份有限公司 用于疼痛治疗的寡核苷酸诱饵
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
KR20240113607A (ko) 2017-06-21 2024-07-22 트랜스진 개인 맞춤형 백신
CA3093093A1 (en) 2018-03-07 2019-09-12 Transgene Parapoxvirus vectors
CA3124773A1 (en) 2018-12-28 2020-07-02 Transgene M2-defective poxvirus
WO2022148736A1 (en) 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5734033A (en) * 1988-12-22 1998-03-31 The Trustees Of The University Of Pennsylvania Antisense oligonucleotides inhibiting human bcl-2 gene expression
US6153737A (en) 1990-01-11 2000-11-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
JPH04352724A (ja) * 1990-07-27 1992-12-07 Mitsui Toatsu Chem Inc 免疫調節型治療剤
EP0468520A3 (en) * 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
AU2580892A (en) 1991-09-05 1993-04-05 Isis Pharmaceuticals, Inc. Determination of oligonucleotides for therapeutics, diagnostics and research reagents
DE69429617T2 (de) * 1993-04-30 2002-08-22 Biognostik Gesellschaft Fuer Biomolekulare Diagnostik Mbh Antisense-oligonukleotide zur behandlung des immunsuppressiven effektes des transformierenden wachstumsfaktor-beta1(tgf-beta1)
EP0708829B8 (en) * 1993-07-10 2004-07-21 BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH A pharmaceutical composition comprising antisense-nucleic acid for prevention and/or treatment of neuronal injury, degeneration and cell death and for the treatment of neoplasms
US6001982A (en) 1993-07-29 1999-12-14 Isis Pharmaceuticals, Inc. Synthesis of oligonucleotides
CA2172153C (en) * 1993-09-20 2010-03-09 John C. Reed Regulation of bcl-2 gene expression
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5563255A (en) * 1994-05-31 1996-10-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AU713040B2 (en) * 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6160109A (en) 1995-10-20 2000-12-12 Isis Pharmaceuticals, Inc. Preparation of phosphorothioate and boranophosphate oligomers
US6280978B1 (en) * 1995-12-15 2001-08-28 Intronn Holdings, Llc Methods and compositions for use in spliceosome mediated RNA trans-splicing
EP0914324B1 (en) * 1996-05-22 2001-12-05 McGILL UNIVERSITY Specific inhibitors of dna methyltransferase enzyme
EP0855184A1 (en) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
US5965420A (en) * 1997-03-05 1999-10-12 Smithkline Beecham Corporation Human protein kinases hYAK3
WO1998055609A1 (en) * 1997-06-06 1998-12-10 The Regents Of The University Of California Inhibitors of dna immunostimulatory sequence activity
DE69829984D1 (de) * 1997-08-29 2005-06-02 Univ California Modulatoren der cytosin-5-methyl-transferase und verfahren zu ihrer verwendung
PT1009413E (pt) * 1997-09-05 2007-05-31 Univ California Utilização de oligonucleótidos imumoestimulantes para a prevenção ou tratamento da asma.
US5874416A (en) * 1997-11-07 1999-02-23 Sheikhnejad; Gholamreza RAS antisense inhibition
US6060310A (en) 1997-11-24 2000-05-09 The United States Of America As Represented By The Department Of Health And Human Services Transcription factor decoy and tumor growth inhibitor
US6020475A (en) 1998-02-10 2000-02-01 Isis Pharmeuticals, Inc. Process for the synthesis of oligomeric compounds
US6218371B1 (en) * 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US6562798B1 (en) * 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6166239A (en) 1998-09-04 2000-12-26 Isis Pharmaceuticals, Inc. Oligonucleotide protecting groups
JP2003524602A (ja) 1998-09-18 2003-08-19 ダイナバックス テクノロジーズ コーポレイション ＩｇＥ関連疾患の治療方法と、その治療において使用する組成物
US6069243A (en) 1998-10-06 2000-05-30 Isis Pharmaceuticals, Inc. Process for oligonucleotide synthesis
CA2344558A1 (en) 1998-10-09 2000-04-20 Dynavax Technologies Corporation Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens
US6169177B1 (en) 1998-11-06 2001-01-02 Isis Pharmaceuticals, Inc. Processes for the synthesis of oligomeric compounds
US6121437A (en) 1999-03-16 2000-09-19 Isis Pharmaceuticals, Inc. Phosphate and thiophosphate protecting groups
FR2790955B1 (fr) * 1999-03-19 2003-01-17 Assist Publ Hopitaux De Paris Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
KR20020006037A (ko) 1999-04-19 2002-01-18 스티븐 아이. 밀러 세리아 및 백금족 금속을 포함하는 촉매 조성물
AU780724B2 (en) * 2000-01-14 2005-04-14 Migenix Inc. Derivatives of polyene macrolides and preparation and use thereof

Also Published As

Publication number Publication date
WO2000056342A3 (fr) 2001-07-26
EP1162982B1 (fr) 2005-02-09
EP1162982A2 (fr) 2001-12-19
DK1162982T3 (da) 2005-06-13
ES2235839T3 (es) 2005-07-16
PT1162982E (pt) 2005-05-31
WO2000056342A2 (fr) 2000-09-28
JP2002539265A (ja) 2002-11-19
DE60018050D1 (de) 2005-03-17
US7700569B1 (en) 2010-04-20
CA2371990A1 (fr) 2000-09-28
AU3300600A (en) 2000-10-09
US20020192184A1 (en) 2002-12-19
FR2790955B1 (fr) 2003-01-17
FR2790955A1 (fr) 2000-09-22
EP1162982B9 (fr) 2005-07-06
ATE288759T1 (de) 2005-02-15
US7108844B2 (en) 2006-09-19

Similar Documents

Publication Publication Date Title
US7700569B1 (en) Use of stabilised oligonucleotides for preparing a medicine with antitumor activity
DE60131430T2 (de) Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
DE69028694T2 (de) Verfahren und zubereitungen zur krebsbehandlung mit oligonukleotiden
DE69929444T2 (de) Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
DE69535036T2 (de) Immunomodulatorische oligonukleotide
Grossman Chemically induced epileptiform seizures in the cat
DE69736331T2 (de) Immunstimulierende nukleinsaeuremolekuele
EP2658566B1 (de) Sirna gegen cbl-b kombiniert mit zytokinen und interferonen in der behandlung von krebs
DE3833319C2 (enExample)
EP1223980B1 (de) Verwendung von csf-1-inhibitoren
DE60132170T2 (de) MODULIERUNG DER DURCH CpG-OLIGONUKLEOTIDE VERURSACHTEN IMMUNSTIMULIERUNG DURCH POSITIONSBEDINGTE VERÄNDERUNG VON NUKLEOSIDEN
DE69433590T2 (de) Zellulärer impfstoff und deren verwendung für die behandlung von malignen, soliden tumoren
DE19935756A1 (de) Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
DE60036019T2 (de) Synthetische oligonukleotide die therapeutisch nützlich sind
WO2006015560A1 (de) Immunmodulierendes mittel in verbindung mit chemotherapeutischen massnahmen
DE69719785T2 (de) Zusammensetzung aus brustkrebszellen, die mit einem gegen den rezeptor für insulin-ähnlichen wachstumsfaktor gerichteten antisens-oligonukleotidbehandelt worden sind.
EP1441759A2 (de) Zelluläre impfstoffe mit adjuvanzien
EP1699480A1 (de) Allogenes tumortherapeutikum
Friedman et al. Chemotherapy of subcutaneous and intracranial human medulloblastoma xenografts in athymic nude mice
DE69830910T2 (de) Kaliumkanal-proteine zur verwendung in gentherapie zur verminderung von erektiler dysfunktion
DE19750702A1 (de) Antisense Oligonucleotide gegen Tenascin zur Behandlung von Vitiligo
Firth et al. Studies on the intracerebral injection of bleomycin free and entrapped within liposomes in the rat.
Hockman et al. Inhibition of reflex vagal bradycardia by diazepam
DE602004008085T2 (de) Antisense-oligonukleotid zur hemmung der melanom-inhibierenden aktivität (mia)
DE2834893A1 (de) Verfestigtes (festes) pharmazeutisches mittel und verfahren zu seiner herstellung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition